BMO Capital Initiates Coverage On Ascendis Pharma with Outperform Rating, Announces Price Target of $319

Benzinga Newsdesk www.benzinga.com Positive 69.1%

Neg 0% Neu 0% Pos 69.1%

BMO Capital analyst David Lebowitz initiates coverage on Ascendis Pharma (NASDAQ:ASND) with a Outperform rating and announces Price Target of $319.